echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > China's insulin centralized procurement implements "high quality and reasonable price" drugs to benefit a large number of diabetic patients

    China's insulin centralized procurement implements "high quality and reasonable price" drugs to benefit a large number of diabetic patients

    • Last Update: 2022-05-13
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    The Office of the National Medical Insurance Administration and the General Office of the National Health and Health Commission issued the "Notice on Improving the Supporting Measures for the Centralized Procurement and Use of Nationally Organized Drugs (Insulin Special)"
    .
    The reporter learned on the 5th that the average price of the drugs selected for the insulin special project was reduced by 48%, which is expected to save a lot of medical insurance expenses
    .
     
    It is understood that the "group purchase" of the "national team" is patient-centered, fully respects clinical choices, maintains the stability of clinical drug varieties, and reduces the risk of substitution, and a variety of insulins have been included in the scope of centralized procurement
    .
    Among them, Laiyoushi? and come time? As the original basal insulin, the average daily treatment cost has been reduced to less than 5 yuan, greatly improving the availability of "high-quality and affordable" drugs, which is a great news for a large number of diabetic patients in China
    .
     
    In fact, the treatment rate and compliance rate of diabetes in China are still at a low level, which leads to the increase of complications, which not only seriously affects the life and quality of life of patients, but also brings a heavy burden to the national medical expenditure
    .
    Diabetes requires long-term management, which places higher requirements on the efficacy, safety and accessibility of medicines
    .
     
    Professor Zhu Dalong, chairman of the Diabetes Branch of the Chinese Medical Association, introduced: "Insulin, as an important drug for diabetic patients to control blood sugar, plays an irreplaceable role in achieving blood sugar standards
    .
    According to the "China Guidelines for the Prevention and Treatment of Type 2 Diabetes (2020 Edition)", oral For patients with poor drug control, it is recommended to start using basal insulin therapy
    .
    As a new generation of basal insulin, Layoushi? can effectively help patients achieve stable glucose control and reduce the risk of hypoglycemia, and is more effective for the elderly and patients with renal insufficiency.
    At the same time, its innovative mechanism and process enhance the patient experience in terms of injection flexibility and comfort, and further improve compliance
    .
    "
     
      Community and county-level primary care systems are the first line of defense for chronic disease management
    .
    The substantial price reduction of the original basal insulin has enabled a wider range of grassroots diabetic patients to use the world's advanced therapeutic drugs, and has become an important basis for standardized diabetes management
    .
    Insulin "group-purchased" in the name of the "national team" will gradually arrive in the hands of patients in May
    .
    It is understood that patients can obtain medicines through channels such as hospitals , community pharmacies , and Internet hospitals
    .
    (Finish)
      The Office of the National Medical Insurance Administration and the General Office of the National Health and Health Commission issued the "Notice on Improving the Supporting Measures for the Centralized Procurement and Use of Nationally Organized Drugs (Insulin Special)"
    .
    The reporter learned on the 5th that the average price of the drugs selected for the insulin special project was reduced by 48%, which is expected to save a lot of medical insurance expenses
    .
     
      It is understood that the "group purchase" of the "national team" is patient-centered, fully respects clinical choices, maintains the stability of clinical drug varieties, and reduces the risk of substitution, and a variety of insulins have been included in the scope of centralized procurement
    .
    Among them, Laiyoushi? and come time? As the original basal insulin, the average daily treatment cost has been reduced to less than 5 yuan, greatly improving the availability of "high-quality and affordable" drugs, which is a great news for a large number of diabetic patients in China
    .
     
      In fact, the treatment rate and compliance rate of diabetes in China are still at a low level, which leads to the increase of complications, which not only seriously affects the life and quality of life of patients, but also brings a heavy burden to the national medical expenditure
    .
    Diabetes requires long-term management, which places higher requirements on the efficacy, safety and accessibility of medicines
    .
     
      Professor Zhu Dalong, chairman of the Diabetes Branch of the Chinese Medical Association, introduced: "Insulin, as an important drug for diabetic patients to control blood sugar, plays an irreplaceable role in achieving blood sugar standards
    .
    According to the "China Guidelines for the Prevention and Treatment of Type 2 Diabetes (2020 Edition)", oral For patients with poor drug control, it is recommended to start using basal insulin therapy
    .
    As a new generation of basal insulin, Layoushi? can effectively help patients achieve stable glucose control and reduce the risk of hypoglycemia, and is more effective for the elderly and patients with renal insufficiency.
    At the same time, its innovative mechanism and process enhance the patient experience in terms of injection flexibility and comfort, and further improve compliance
    .
    "
     
      Community and county-level primary care systems are the first line of defense for chronic disease management
    .
    The substantial price reduction of the original basal insulin has enabled a wider range of grassroots diabetic patients to use the world's advanced therapeutic drugs, and has become an important basis for standardized diabetes management
    .
    Insulin "group-purchased" in the name of the "national team" will gradually arrive in the hands of patients in May
    .
    It is understood that patients can obtain medicines through channels such as hospitals , community pharmacies , and Internet hospitals
    .
    (Finish)
      The Office of the National Medical Insurance Administration and the General Office of the National Health and Health Commission issued the "Notice on Improving the Supporting Measures for the Centralized Procurement and Use of Nationally Organized Drugs (Insulin Special)"
    .
    The reporter learned on the 5th that the average price of the drugs selected for the insulin special project was reduced by 48%, which is expected to save a lot of medical insurance expenses
    .
     
      It is understood that the "group purchase" of the "national team" is patient-centered, fully respects clinical choices, maintains the stability of clinical drug varieties, and reduces the risk of substitution, and a variety of insulins have been included in the scope of centralized procurement
    .
    Among them, Laiyoushi? and come time? As the original basal insulin, the average daily treatment cost has been reduced to less than 5 yuan, greatly improving the availability of "high-quality and affordable" drugs, which is a great news for a large number of diabetic patients in China
    .
    medicines medicines medicines
     
      In fact, the treatment rate and compliance rate of diabetes in China are still at a low level, which leads to the increase of complications, which not only seriously affects the life and quality of life of patients, but also brings a heavy burden to the national medical expenditure
    .
    Diabetes requires long-term management, which places higher requirements on the efficacy, safety and accessibility of medicines
    .
     
      Professor Zhu Dalong, chairman of the Diabetes Branch of the Chinese Medical Association, introduced: "Insulin, as an important drug for diabetic patients to control blood sugar, plays an irreplaceable role in achieving blood sugar standards
    .
    According to the "China Guidelines for the Prevention and Treatment of Type 2 Diabetes (2020 Edition)", oral For patients with poor drug control, it is recommended to start using basal insulin therapy
    .
    As a new generation of basal insulin, Layoushi? can effectively help patients achieve stable glucose control and reduce the risk of hypoglycemia, and is more effective for the elderly and patients with renal insufficiency.
    At the same time, its innovative mechanism and process enhance the patient experience in terms of injection flexibility and comfort, and further improve compliance
    .
    "
     
      Community and county-level primary care systems are the first line of defense for chronic disease management
    .
    The substantial price reduction of the original basal insulin has enabled a wider range of grassroots diabetic patients to use the world's advanced therapeutic drugs, and has become an important basis for standardized diabetes management
    .
    Insulin "group-purchased" in the name of the "national team" will gradually arrive in the hands of patients in May
    .
    It is understood that patients can obtain medicines through channels such as hospitals , community pharmacies , and Internet hospitals
    .
    (Finish)
    Hospital Hospital Hospital Pharmacy Pharmacy Pharmacy
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.